Publicaciones (78) Publicaciones de RAFAEL LEÓN MARTÍNEZ

2024

  1. Discovery of a potent melatonin-based inhibitor of quinone reductase-2 with neuroprotective and neurogenic properties

    European Journal of Medicinal Chemistry, Vol. 277

  2. Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment

    Medicinal Research Reviews, Vol. 44, Núm. 6, pp. 2367-2419

  3. TRP14 is the rate-limiting enzyme for intracellular cystine reduction and regulates proteome cysteinylation

    EMBO Journal, Vol. 43, Núm. 13, pp. 2789-2812

  4. The Melatonin Derivative ITH13001 Prevents Hypertension and Cardiovascular Alterations in Angiotensin II-Infused Mice

    The Journal of pharmacology and experimental therapeutics, Vol. 388, Núm. 2, pp. 670-687

2023

  1. KEAP1-NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

    Medicinal Research Reviews, Vol. 43, Núm. 1, pp. 237-287

2022

  1. Curcumin-piperlongumine hybrids with a multitarget profile elicit neuroprotection in in vitro models of oxidative stress and hyperphosphorylation

    Antioxidants, Vol. 11, Núm. 1

  2. Enantioselective Synthesis and Pharmacological Evaluation of Aza‐CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer’s Disease

    Antioxidants, Vol. 11, Núm. 1

  3. Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease

    Antioxidants, Vol. 11, Núm. 2

  4. Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades

    Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4727-4751

2021

  1. Bisavenathramide analogues as nrf2 inductors and neuroprotectors in in vitro models of oxidative stress and hyperphosphorylation

    Antioxidants, Vol. 10, Núm. 6

  2. Enhanced stability and bioactivity of natural anticancer topoisomerase i inhibitors through cyclodextrin complexation

    Pharmaceutics, Vol. 13, Núm. 10

  3. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches

    Handbook of Experimental Pharmacology (Springer Science and Business Media Deutschland GmbH), pp. 229-259

2020

  1. Antioxidant, anti-inflammatory and neuroprotective profiles of novel 1,4-dihydropyridine derivatives for the treatment of alzheimer’s disease

    Antioxidants, Vol. 9, Núm. 8, pp. 1-20

  2. Aza-CGP37157-lipoic hybrids designed as novel Nrf2-inducers and antioxidants exert neuroprotection against oxidative stress and show neuroinflammation inhibitory properties

    Drug Development Research, Vol. 81, Núm. 3, pp. 283-294

  3. Ciclohexadienales quirales en la síntesis de nuevos neuroprotectores

    VI Jornadas de Investigadoras de Castilla y León: la aventura de la ciencia y la tecnología (Fundación 3CIN), pp. 54

  4. Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization

    Pharmacological Research, Vol. 152

  5. NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases

    Biomolecules, Vol. 10, Núm. 6

  6. New Nrf2-inducer compound ITH12674 slows the progression of retinitis pigmentosa in the mouse model rd10

    Cellular Physiology and Biochemistry, Vol. 54, Núm. 1, pp. 142-159

  7. Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties

    European Journal of Medicinal Chemistry, Vol. 190

  8. When it comes to an end: Oxidative stress crosstalk with protein aggregation and neuroinflammation induce neurodegeneration

    Antioxidants, Vol. 9, Núm. 8, pp. 1-34